The company is currently advancing a therapeutic development pipeline with two proprietary technologies — Inflammasome ASC Inhibitor IC 100, targeting inflammasome-driven inflammatory diseases, and Cholesterol Efflux Mediator VAR 200 for treatment of kidney diseases. Management characterizes the next 18 months as transformative, with plans to file an IND in Q4-2026 for IC 100, followed by Phase 1 trial initiation in overweight healthy subjects, with a SAD Phase 1 read-out expected in Q1-2027.
Cyborg Score Rationale
The company raised only $1 million in Q1-2026 and faces significant cash constraints as it approaches critical clinical milestones. While IC 100 represents potentially differentiated technology for multi-inflammasome inhibition, the company's limited funding and OTCQB listing position it as a high-risk, pre-clinical to early-phase asset with execution challenges ahead.
Top Insights
IND filing planned for Q4-2026 for Inflammasome ASC Inhibitor IC 100
VAR 200 Phase 2a trial initiation planned for H2-2026 in orphan disease FSGS and Alport syndrome
Total accessible market for inflammatory and renal diseases exceeds $100 billion
Cash position only covers month-to-month operations; acute funding requirement for clinical advancement
Named Competitors
Inflammasome inhibitors (NLRP3-focused) — Established NLRP3 inflammasome program with clinical validation
Renal disease therapeutics — Advanced-stage kidney disease development programs
Inflammatory disease platforms — Multi-program immunology and inflammatory disease focus
Recent Developments
(February 2026) Completed $1 million private placement of convertible notes and warrants
(Q1 2026) Raised $1 million in funding to support operations